Overview

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.

Eligibility

Inclusion Criteria:

• Aged 2-12 years
• ASA physical status I-II
• Body mass index (BMI): 14-28 kg/m²
• Scheduled for elective tonsillectomy with or without adenoidectomy
• Signed informed consent by legal guardian(s) and assent by children (≥8 years old)

Exclusion Criteria:

• History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA)
• Previous episodes of significant PRAEs
• Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol)
• Comorbidities including: Uncorrected congenital heart disease, neuromuscular disorders, Developmental delay, Abnormal hepatic/renal function
• Preoperative moderate-to-severe respiratory infections requiring surgery postponement
• Recent participation in other clinical trials